Online inquiry

IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5832MR)

This product GTTS-WQ5832MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E gene. The antibody can be applied in Psoriasis, Type 1 diabetes research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916
UniProt ID P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ5832MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3108MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA APN311
GTTS-WQ660MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 8H9
GTTS-WQ49MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ10047MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ9263MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ8909MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IGE25
GTTS-WQ12629MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ12289MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MSB-0010718C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW